Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients (Q44120885)

30 November 2017

title

Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients (English)

1 reference

30 November 2017

0 references

1 reference

coronary artery disease

1 reference

6

Ernst J Schaefer

1 reference

30 November 2017

Bela F Asztalos

1

1 reference

30 November 2017

Katalin V Horvath

2

1 reference

30 November 2017

Judith R McNamara

3

1 reference

30 November 2017

Paul S Roheim

4

1 reference

30 November 2017

Joel J Rubinstein

5

1 reference

30 November 2017

publication date

1 October 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

164

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

361-369

1 reference

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Cholesterol reduction yields clinical benefit: impact of statin trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Triglycerides and atherogenic lipoproteins: rationale for lipid management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Lowering effects of four different statins on serum triglyceride level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

10.1016/S0021-9150(02)00149-1

7 January 2021

Identifiers

DOI

1 reference

release_3hovc2uchrbldgaera4rnhyp7i

30 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3hovc2uchrbldgaera4rnhyp7i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference